Autoimmune diabetes

September 27, 2018

A probiotic way to say no to autoimmune diabetes: Probiotic Lactococcus lactis  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 27/September/2018, 8.10 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
September 8, 2018

Live-attenuated pneumococcal vaccine-based therapy for autoimmune diabetes (TIDM):  Live-attenuated pneumococcal vaccine, known to protect against infections caused by pneumonia,  increases the expression of PD-L1, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 8/September/2018, 11.41 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
August 23, 2018

Thyroid hormones come to the rescue of blood sugar disease: Levothyroxine (T4) and Liothyronine(T3)-based therapy for autoimmune diabetes (TIDM): Thyroxine/Levothyroxine (T4) and Liothyronine/Triiodothyronine (T3) increase PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 23/August/2018, 11.35 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
July 24, 2018

Vasoactive intestinal polypeptide (VIP)-based therapy for blood sugar disease (autoimmune diabetes (TIDM)): Vasoactive intestinal polypeptide (VIP), a peptide hormone known to play a role in heart contractility, vasodilation, and blood pressure,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 24/July/2018,  10.24 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]